



ARDOZ HEALTHCARE BV

Oxygen: the new Gold Standard



company presentation

August 2017

Ardoz Healthcare B.V.
Kasteleinenkampweg 9C
5222 AX 's-Hertogenbosch
The Netherlands
PO-box 2057, 5202 CB 's-Hertogenbosch
The Netherlands



ISO 13485




Tel: +31(0)73 627 07 40
Internet: www.ardoz.com
E-mail: info@ardoz.com

The technology behind Ardox-X[®]

After 10 years of research:

Ardoz Healthcare developed a mechanism that releases stabilized oxygen particles in a controlled manner.



The technology behind Ardox-X®

Ardoz Healthcare is at the cutting edge of developing new products for oral care and dermatology treatment.

Ardox-X®

Ardox-X® is a patented complex that provides a controlled release of (safe) active oxygen without generating hydroxyl radicals. Ardox-X® can be used in skin care products to safely replace existing active ingredients that provide anti-bacterial action. Contrary to the ingredients it replaces Ardox-X® causes no negative side effects.



The technology behind Ardox-X®

<u>Chemical class:</u>	<u>Stabilized Active Oxygen donating complex</u>
<i>Mechanism of action:</i>	Anti-allergic, anti-fungal, whitening agent. Safe replacement for: cortisones, antibiotics, anti-fungals, peroxides and chlorhexidine.
<i>Formulations:</i>	Cream, gel, balm, spray, shampoo, toothpaste, rinse, whitening gel.
<i>Regulatory:</i>	All ingredients are registered and approved for cosmetics and Medical Devices.



The technology behind Ardox-X[®]

Other technologies

New mile stones have been reached in the field of periodontitis, peri-implantitis and gingivitis.

Research and Development

Ardoz Healthcare has done extensive research on the Ardox-X[®] technology, not only performed in-house, but also at leading institutions world wide such as, ACTA Amsterdam, Loma Linda University California, Tuft's University Indiana, Nijmegen University, AMC Amsterdam, Rijnstate Hospital Arnhem, Bartholemew's Oxford, TNO The Hague, Leicester School of Pharmacy, De Montfort University Leicester, and many others.



A technology similar in ways to Hyperbaric oxygen

For over 50 years, medical science has upheld the therapeutic effects of safe (non radical) oxygen in treating a wide range of health conditions.

Hyperbaric oxygen heals:

- Initiates neo-vascularization
- Blocks histamine release
- All without negative side effects



Ardoz Healthcare has earned a reputation for effective and safe products

Since 2012, Ardoz Healthcare has developed and distributed Ardox-X® based products for private label use for both therapeutic use and oral hygiene in Europe



Ardoz Healthcare Cosmetic products

Dental Implant Treatment & Maintenance

- No anti-biotics
- Continued use prevents implant and gum problems

Oral
Care
Market



Sold under the name Implaclean and Miraclin Implant



Ardoz Healthcare Cosmetic products

Dental Oral Hygiene

Mouthwash / Tooth paste

- Kills only (bad) anaerobic bacteria
- pH neutral
- No Alcohol
- Contains Ardox-X® active oxygen
- Sodium Fluoride
- Positive side effects; helps prevent cavities and bad breath
- Daily use, preventive, curative and post-operative
- No side effects as with chlorhexidine

Sold under the name O7 Active in Europe

Oral
Care
Market



Ardoz Healthcare Cosmetic products

Dental Oral Hygiene

End 2011 the European Commission banned tooth whiteners with more than 0.1% hydrogen peroxide from the consumer market.

Our product, whitening pen is now the only legal retail consumer product.

- 100% peroxide free
- up to 4 shades whitening effect.

Sold under the name Miradent Mirawhite Shine in Europe

Oral
Care
Market



Ardoz Healthcare treatments (Medical Device class 2A)

Annex I to Certificate Z/16/03912E
Date of Revision: December 9th, 2016
Number of Pages: 1 of 1



This certificate is valid for the hereafter following devices:

Name of product category	Name of individual type	Nomenclature code ¹
Single use devices	Ardoz Balm Ardoz Calming Spray Ardoz Shampoo Ardoz Cream	/
Single use devices	Active Oxygen Gel and Mouthwash	/

Special terms of validity:

In case of class I products or sterile procedure packs acc. to article 12 (3) of the Directive 93/42/EEC the intervention of ecm is limited to aspects of manufacture concerned with securing and maintaining sterile conditions respectively the conformity with the metrological requirements.

¹ UMDNS Code is optional

Oral
Care
Market

Derma
Care
Market



Ardoz Healthcare treatments (Medical Device class 2A)

NEW: INTRODUCTION 2017

- GINGIVITIS
- PERIODONTITIS
- PERI-IMPLANTITIS

Unique healing properties such as:

- selective elimination of ONLY pathogenic bacteria(!)
recent research done by ACTA Amsterdam shows that the beneficial bacteria in the oral cavity are essential for supporting health in the body a.o. lowering high blood pressure. Ardox-X® protects these species.
- penetration/removal of the biofilm (drastically reducing caries)

Oral
Care
Market



Ardoz Healthcare treatments (Medical Device class 2A)

Products

- Ardoz Active Oxygen gel
- Active Oxygen mouthwash



Oral
Care
Market


These products are sold under the name of Oxysafe gel and Oxysafe liquid and O7 professional in Europe.



Least adverse events in randomised 200 patient study

Ardox-X[®] toothpaste had equal efficacy but much lower adverse events (teeth staining and desquamation) in comparison with other leading anti-bacterial toothpastes

Oral
Care
Market



Ardox-X® therapeutic dermatology products (Medical Device class 2A)

Therapeutic products on the market under private label:

- Eczema Cream
- Psoriasis Balm
- Psoriasis Shampoo
- Psoriasis Spray




Derma
Care
Market

Products sold under the name Kruidvat Eczema Cream and Kruidvat Psoriasis Balm
Trekpleister Eczema Cream
PSO2 Balm, PSO2 Shampoo and
PSO2 Olio Spray in Italy via pharmacists



Successful Dermacare treatment of eczema and psoriasis



Results after 7 months of using Ardox-X® Psoriasis Balm

Study of 104 psoriasis patients, with an average treatment of 5 to 7 months.

Derma
Care
Market



How Ardoz healthcare has earned this reputation of Dermatology products (Medical Device class 2a)

Exceptional safety and efficacy recognised

Successful tests at Derma Test on patients with different types of psoriasis in Germany have resulted in sales of over 1.000.000 of our private label derma care products. Our continued improvements to the products have established a record of safe use for the Ardox-X[®] technology



Derma
Care
Market



Clinical Trials and Laboratory Testing

Clinical studies and trials performed world-wide have demonstrated the safety and efficacy of Ardox-X® technology

In 2013 ACTA Amsterdam has demonstrated after 4 years of research that Ardox-X® has unique properties such as selective anti-bacterial action.

Markets need new treatments

Clinical Studies on Ardox-X® Technology

Date of Trial	2003	2004	2005	2005
Type of Clinical Trial/Study	Phase II	Phase II	Phase II	Phase III
Location	Schulke & Mayr (D)	Schulke & Mayr (D)	University of Aberdeen (UK)	TNO, Leiden (NL)
Purpose	Challenge test	Challenge test	In vitro anti-fungal test	Study of Angiogenesis: in-vivo application in mice
Doctor Leading Trial/ Department	Matthew Daulby, Microbiology laboratory	Matthew Daulby, Microbiology laboratory	Prof. F. C. Odds/Inst. For Med. Sciences	Pieter Koolwijk, Ph. D.
Compound Tested	Several Ardox-X® concentrations	Several Ardox-X® concentrations	[Ardox-X®] = 20 eq; onychomycosis gel	Several Ardox-X® concentrations
Results	Ardox-X® products showed broad anti-bacterial properties	Parts of the technology showed anti-bacterial properties, but only the complete technology exhibits a full anti-bacterial spectrum	Ardox-X® gel has a good clinical potential to be used as a topical anti-fungal agent. The complex showed efficacy against a range of fungi associated with skin and nail infections	Ardox-X® technology stimulates angiogenesis and thus woundhealing
Study Number	Study nr. 03-010	Study nr. 04-001	Study nr. 05-001 and 05-002	Study nr. 05-006

2003 Phase I

Mubio products BV (NL)

Effect of oxygen donors on DNA damage

Prof. F. Ramaekers, the University of Maastricht

Ardox-X® Whitening gel

The whitening gel shows very limited DNA damage in cells when treated with high concentrated Ardox-X® gel

Study nr. 03-008

1999 Phase II

Royal London School of Medicine and Dentistry (UK)

Efficacy, Chemical model studies of neutralising oral malodour by Ardox-X® whitening gel

Prof. E. Lynch/Dr M. Grootveld/ Medicine & Dentistry Department

Several Ardox-X® technologies

Chemical structure of Ardox-X® whitening gel indicates potential efficacy against oral malodour cysteine and methionine species

Study nr. 02-005, 02-006

